Akebia Therapeutics, Inc.
PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE

Last updated:

Abstract:

The present disclosure relates to HIF-1.alpha. prolyl hydroxylase inhibitors, compositions which comprise the HIF-1.alpha. prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Status:
Application
Type:

Utility

Filling date:

22 Jun 2020

Issue date:

13 May 2021